Hereditary Optic Neuropathies: A Systematic Review on the Interplay Between Biomaterials and Induced Pluripotent Stem Cells

Overview

Journal Bioengineering (Basel)

Date 2024 Jan 22

PMID 38247929

Authors

Miguel Ladero

Jose Alberto Reche-Sainz

M Esther Gallardo

Affiliations

Soon will be listed here.

Abstract

Hereditary optic neuropathies (HONs) such as dominant optic atrophy (DOA) and Leber Hereditary Optic Neuropathy (LHON) are mitochondrial diseases characterized by a degenerative loss of retinal ganglion cells (RGCs) and are a cause of blindness worldwide. To date, there are only limited disease-modifying treatments for these disorders. The discovery of induced pluripotent stem cell (iPSC) technology has opened several promising opportunities in the field of HON research and the search for therapeutic approaches. This systematic review is focused on the two most frequent HONs (LHON and DOA) and on the recent studies related to the application of human iPSC technology in combination with biomaterials technology for their potential use in the development of RGC replacement therapies with the final aim of the improvement or even the restoration of the vision of HON patients. To this purpose, the combination of natural and synthetic biomaterials modified with peptides, neurotrophic factors, and other low- to medium-molecular weight compounds, mimicking the ocular extracellular matrices, with human iPSC or iPSC-derived cell retinal progenitors holds enormous potential to be exploited in the near future for the generation of transplantable RGC populations.

References

Han I, Bohrer L, Gibson-Corley K, Wiley L, Shrestha A, Harman B . Biocompatibility of Human Induced Pluripotent Stem Cell-Derived Retinal Progenitor Cell Grafts in Immunocompromised Rats. Cell Transplant. 2022; 31:9636897221104451. PMC: 9247396. DOI: 10.1177/09636897221104451. View

Ortuno-Costela M, Rodriguez-Mancera N, Garcia-Lopez M, Zurita-Diaz F, Moreno-Izquierdo A, Lucia A . Establishment of a human iPSC line (IISHDOi001-A) from a patient with McArdle disease. Stem Cell Res. 2017; 23:188-192. DOI: 10.1016/j.scr.2017.07.020. View

Li Z, Keel S, Liu C, He M . Can Artificial Intelligence Make Screening Faster, More Accurate, and More Accessible?. Asia Pac J Ophthalmol (Phila). 2018; 7(6):436-441. DOI: 10.22608/APO.2018438. View

Chen B, Harvey J, Gilhooley M, Jurkute N, Yu-Wai-Man P . Mitochondria and the eye-manifestations of mitochondrial diseases and their management. Eye (Lond). 2023; 37(12):2416-2425. PMC: 10397317. DOI: 10.1038/s41433-023-02523-x. View

Meyerson C, Van Stavern G, McClelland C . Leber hereditary optic neuropathy: current perspectives. Clin Ophthalmol. 2015; 9:1165-76. PMC: 4492634. DOI: 10.2147/OPTH.S62021. View

Kador K, Grogan S, Dorthe E, Venugopalan P, Malek M, Goldberg J . Control of Retinal Ganglion Cell Positioning and Neurite Growth: Combining 3D Printing with Radial Electrospun Scaffolds. Tissue Eng Part A. 2016; 22(3-4):286-94. PMC: 4779292. DOI: 10.1089/ten.TEA.2015.0373. View

Carelli V, La Morgia C, Yu-Wai-Man P . Mitochondrial optic neuropathies. Handb Clin Neurol. 2023; 194:23-42. DOI: 10.1016/B978-0-12-821751-1.00010-5. View

Casari G, De Fusco M, Ciarmatori S, Zeviani M, Mora M, Fernandez P . Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell. 1998; 93(6):973-83. DOI: 10.1016/s0092-8674(00)81203-9. View

Yang T, Chuang J, Buddhakosai W, Wu W, Lee C, Chen W . Elongation of Axon Extension for Human iPSC-Derived Retinal Ganglion Cells by a Nano-Imprinted Scaffold. Int J Mol Sci. 2017; 18(9). PMC: 5618661. DOI: 10.3390/ijms18092013. View

10.

Kim U, Mahroo O, Mollon J, Yu-Wai-Man P . Retinal Ganglion Cells-Diversity of Cell Types and Clinical Relevance. Front Neurol. 2021; 12:661938. PMC: 8175861. DOI: 10.3389/fneur.2021.661938. View

11.

Nicolas J, Magli S, Rabbachin L, Sampaolesi S, Nicotra F, Russo L . 3D Extracellular Matrix Mimics: Fundamental Concepts and Role of Materials Chemistry to Influence Stem Cell Fate. Biomacromolecules. 2020; 21(6):1968-1994. DOI: 10.1021/acs.biomac.0c00045. View

12.

Sluch V, Davis C, Ranganathan V, Kerr J, Krick K, Martin R . Differentiation of human ESCs to retinal ganglion cells using a CRISPR engineered reporter cell line. Sci Rep. 2015; 5:16595. PMC: 4643248. DOI: 10.1038/srep16595. View

13.

Kim S, Min S, Choi Y, Jo S, Jung J, Han K . Tissue extracellular matrix hydrogels as alternatives to Matrigel for culturing gastrointestinal organoids. Nat Commun. 2022; 13(1):1692. PMC: 8967832. DOI: 10.1038/s41467-022-29279-4. View

14.

Lenaers G, Neutzner A, Le Dantec Y, Juschke C, Xiao T, Decembrini S . Dominant optic atrophy: Culprit mitochondria in the optic nerve. Prog Retin Eye Res. 2020; 83:100935. DOI: 10.1016/j.preteyeres.2020.100935. View

15.

Luis J, Eastlake K, Lamb W, Limb G, Jayaram H, Khaw P . Cell-Based Therapies for Glaucoma. Transl Vis Sci Technol. 2023; 12(7):23. PMC: 10383000. DOI: 10.1167/tvst.12.7.23. View

16.

Smith C, Vianna J, Chauhan B . Assessing retinal ganglion cell damage. Eye (Lond). 2017; 31(2):209-217. PMC: 5306472. DOI: 10.1038/eye.2016.295. View

17.

Hunt N, Hallam D, Karimi A, Mellough C, Chen J, Steel D . 3D culture of human pluripotent stem cells in RGD-alginate hydrogel improves retinal tissue development. Acta Biomater. 2016; 49:329-343. DOI: 10.1016/j.actbio.2016.11.016. View

18.

Barbullushi K, Abati E, Rizzo F, Bresolin N, Comi G, Corti S . Disease Modeling and Therapeutic Strategies in CMT2A: State of the Art. Mol Neurobiol. 2019; 56(9):6460-6471. DOI: 10.1007/s12035-019-1533-2. View

19.

Chen A, Brady L, Bulman D, Sundaram A, Rodriguez A, Margolin E . An evaluation of genetic causes and environmental risks for bilateral optic atrophy. PLoS One. 2019; 14(11):e0225656. PMC: 6876833. DOI: 10.1371/journal.pone.0225656. View

20.

Finsterer J, Mancuso M, Pareyson D, Burgunder J, Klopstock T . Mitochondrial disorders of the retinal ganglion cells and the optic nerve. Mitochondrion. 2017; 42:1-10. DOI: 10.1016/j.mito.2017.10.003. View